The health status of children born to mothers with persistent galactorrhea syndrome - amenorrhea treated with parlodel

Abstract

A dopamine agonist - bromo-a-ergocriptine (parlodel) is traditionally used in the treatment of persistent galactorrhea-amenorrhea syndrome (SGA) [11, 13, 19]. Parlodel reduces the frequency of mitoses and the number of secretory granules in the lactotrophs of the adenohypophysis [50], and is capable of slowing the growth of prolactin-secreting pituitary adenomas [1, 40].
 According to a number of authors [5, 11, 13, 56], the dosage and timing of the use of the drug depend on the form of LNG. According to most researchers [6, 17, 19, 24, 29], the effectiveness of its use correlates with the form of the disease. However, the effectiveness of parlodel therapy is apparently also influenced by the functioning of the dopaminergic system (DAS) of a particular patient [15].